A retrospective study evaluating effectiveness and safety of Antihemophilic Factor (Recombinant), PEGylated for prophylaxis in patients with severe haemophilia A: a real world study
Latest Information Update: 07 Dec 2018
At a glance
- Drugs Rurioctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 07 Dec 2018 New trial record